US wants more information from Roche on Illumina bid

Swiss pharmaceutical group Roche said Tuesday the US Federal Trade Commission had requested additional information on its hostile $5.7-billion (4.2 billion euros) bid for US gene mapper Illumina.

The move means that any acquisition would be delayed by 10 days after Roche complies with the second request. This waiting period can be extended voluntarily by Roche or terminated sooner by the FTC.

"Roche will continue to work closely and cooperatively with the FTC as it conducts its review of the proposed transaction in order to respond to and resolve expeditiously any questions the FTC may have," the Swiss company said in a statement.

Roche's offer ran until February 24 but it has received shares worth only $4.55 million from the US company.

It announced on February 27 that it was extending the offer to March 23.

Roche said it had received some 102,165 shares at a proposed price of $44.50 a share.

The Swiss company said then its price was 64 percent higher that Illumina's closing stock price on December 21, 2011 "the day before market rumours" about the potential bid drove Illumina's significantly higher.

Illumina opposes the offer, saying it "does not reflect Illumina's unique leadership position, business performance and future prospects."

Illumina is a leading provider of for DNA sequencing.

add to favorites email to friend print save as pdf

Related Stories

Roche to take over Genentech for $47 billion

Mar 12, 2009

(AP) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.

US approves Swiss firm's cervical cancer test

Apr 20, 2011

Swiss pharmaceutical giant Roche has been given the green light by US authorities to market its test for screening cervical cancer, the company announced on Wednesday.

Recommended for you

New MCAT shifts focus, will include humanities

9 minutes ago

(HealthDay)—The Medical College Admission Test (MCAT) has been revised, and the latest changes, including more humanities such as social sciences, are due to be implemented next April, according to a report ...

Using feminist theory to understand male rape

11 hours ago

Decades of feminist research have framed rape and sexual assault as a 'women's issue', leaving little room for the experiences of male victims. But a new study published in the Journal of Gender Studies suggests that feminist ...

Simulation-based training improves endoscopy execution

Oct 18, 2014

(HealthDay)—Simulation-based training (SBT) improves clinicians' performance of gastrointestinal endoscopy in both test settings and clinical practice, according to research published in the October issue ...

Data sharing in pharmaceutical industry shows progress

Oct 16, 2014

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

User comments